Apropos gårsdagens oppgang, som skulle ettergåes, Så gikk det 28 min fra Nano mottok vedtaket fra Rek til det var publisert, sa TK.
Innafor, det.
Venter fremdeles på at rek-referatene fra april skal legges ut. Archer!
Å fy faen om den ikke hadde gått igjennom. Nå er vi også on track for å finne ny CEO!
Nordic Nanovector ASA: Annual General Meeting held
Oslo, Norway, 30 May 2018
The Annual General Meeting of Nordic Nanovector ASA (the “Company”) (OSE: NANO) was held today on 30 May in Oslo, Norway.
All proposals were resolved by the Annual General Meeting as presented in the notice convening the general meeting distributed on 8 May 2018.
The complete minutes of the Annual General Meeting are attached to this release, and are available on www.nordicnanovector.com.For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.comAbout Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.
Ekstern link: http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa–annual-general-meeting-held,c2535237
Ekstern link: http://mb.cision.com/Public/9819/2535237/90e9d7a3dc3237d4.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180530.Cision.20180530:BIT:0837:0
Nordic Nanovector ASA: Annual General Meeting held
Oslo, Norway, 30 May 2018
The Annual General Meeting of Nordic Nanovector ASA (the “Company”) (OSE: NANO)
was held today on 30 May in Oslo, Norway.
All proposals were resolved by the Annual General Meeting as presented in the
notice convening the general meeting distributed on 8 May 2018.
The complete minutes of the Annual General Meeting are attached to this release,
and are available on www.nordicnanovector.com.For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.comAbout Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC)
designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to
retain marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and
other immunotherapies for multiple cancer indications. Further information about
the Company can be found at www.nordicnanovector.com.This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Norwegian Securities Trading ActEkstern link: http://www.newsweb.no/index.jsp?messageId=452513
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180530.OBI.20180530S51
Tommel opp til OM Holding, som utøver aktivt eierskap, og som jeg også er enig med. Han hadde forøvrig samme innsigelse ved forrige generalforsamling.
23 Likes
Ser vi kun ny dead cat bounce? Slik som aksjen er nå er det vanskelig å forestille seg at den holder seg stabil på et høyere nivå over lengre tid.
Blir interessant å følge med på om det blir kraftige shorteangrep nå etter generalforsamlingen. Dersom FTF og OM Holding har kalt tilbake aksjer fra short med tanke på GF er det bare å slippe aksjene løs nå.
Styret burde se den her:
2 Likes
Er nok mange som trader på nyhetene, men mye usikkerhet er også ryddet bort i aksjen. og Pengespøkelse er dyttet 12 måneder frem i tid om ikke mer.
Nordic Nanovector: Rainer Boehm, MD elected to Board of Directors
Oslo, Norway, 30 May 2018
Nordic Nanovector ASA (OSE: NANO) today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the company’s Annual General Meeting on 30 May 2018.
Mr Boehm is an oncology expert with nearly 30 years’ product development, commercial and corporate development experience working at Novartis, where since 2014 he has held the role of Chief Commercial & Medical Affairs Officer of Novartis Pharma (Switzerland). He has also held various other senior roles regionally and globally within the Oncology and Pharmaceutical divisions, including Executive Vice President, North America of Novartis Oncology in the US from 2005-2010.
During his tenure at Novartis, Mr Boehm oversaw the commercial launches of various oncology brands in the US and globally including Femara®, Zometa®, Glivec®, among others.
Mr Boehm is a member of the Board of Directors at Cellectis SA and Humanigen Inc.
He has a medical degree from the University of Ulm in Germany, and a Master of Business Administration from Schiller University in France.
Ludvik Sandnes, Chairman of Nordic Nanovector, comments: “The Board is very pleased to welcome Rainer as a member. We are sure that his extensive experience in oncology and commercialisation will be invaluable with regards to the future development of the Company.”
Rainer Boehm added: “I am excited to join the Board and provide strategic input as the Company progresses its lead candidate through clinical development towards commercialisation. Betalutin® could provide an important treatment option for non-Hodgkin’s lymphoma patients and I look forward to working with the Board and the management through this important stage of development for the Company.”
For further information, please contact:
Malene Brondberg, VP, Investor Relations and Corporate Communications
Tel/Cell: + 44 7561 431 762
Email: ir@nordicnanovector.com
Media enquiries:
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com
Ekstern link: http://news.cision.com/nordic-nanovector/r/nordic-nanovector—rainer-boehm–md-elected-to-board-of-directors,c2535261
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180530.Cision.20180530:BIT:0861:0
1 Like
Nordic Nanovector: Rainer Boehm, MD elected to Board of Director
Oslo, Norway, 30 May 2018
Nordic Nanovector ASA (OSE: NANO) today announces that Rainer Boehm, MD was
elected as a member of its Board of Directors at the company’s Annual General
Meeting on 30 May 2018.Mr Boehm is an oncology expert with nearly 30 years’ product development,
commercial and corporate development experience working at Novartis, where since
2014 he has held the role of Chief Commercial & Medical Affairs Officer of
Novartis Pharma (Switzerland). He has also held various other senior roles
regionally and globally within the Oncology and Pharmaceutical divisions,
including Executive Vice President, North America of Novartis Oncology in the US
from 2005-2010.During his tenure at Novartis, Mr Boehm oversaw the commercial launches of
various oncology brands in the US and globally including Femara®, Zometa®,
Glivec®, among others.Mr Boehm is a member of the Board of Directors at Cellectis SA and Humanigen
Inc.He has a medical degree from the University of Ulm in Germany, and a Master of
Business Administration from Schiller University in France.Ludvik Sandnes, Chairman of Nordic Nanovector, comments: “The Board is very
pleased to welcome Rainer as a member. We are sure that his extensive experience
in oncology and commercialisation will be invaluable with regards to the future
development of the Company.”Rainer Boehm added: “I am excited to join the Board and provide strategic input
as the Company progresses its lead candidate through clinical development
towards commercialisation. Betalutin® could provide an important treatment
option for non-Hodgkin’s lymphoma patients and I look forward to working with
the Board and the management through this important stage of development for the
Company.”For further information, please contact:
Malene Brondberg, VP, Investor Relations and Corporate Communications
Tel/Cell: + 44 7561 431 762
Email: ir@nordicnanovector.com
Media enquiries:
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information about the Company can be found
at www.nordicnanovectoEkstern link: http://www.newsweb.no/index.jsp?messageId=452522
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180530.OBI.20180530S60
4 Likes
Husk at de fleste ikke er inne. Snart begynner vel konspirasjonsteoretikerne å jobbe igjen. 50-tallet er en gavepakke av dimensjoner.
Håper faktisk at aksjen holder seg lav til over sommeren.
Nye penger kommer inn som kan brukes til mer kjøp.
1 Like
Lisa lovet mer informasjon om Archer-1 så snart formell godkjennelse foreligger fra REK. Jeg tror at en avklaring mellom komiteleder og Kolstad om foenkling av pasientinformasjon vil komme raskt.
Dessuten antydet Lisa nye snarlige oppdateringer på Paradigme.
Dette er vel to kortsiktige trigger i juni.
7 Likes
Godt poeng Jefferson. Ekstrem risiko å ikke sitte med Nano nå. Kun 20 børsdager igjen før sommeren. På en av de dagene kommer det melding om Paradigme. Folk har tydeligvis mistet tillit og tror ikke på at dette skjer. Kjøpt enda mer i dag på 55
20 børsdager?
CVG, er vel rundt 4 uker til 1. juli. 4x5 er 20 dager hvor melding om første pasient kommer, hvis vi skal tro på ledelsen (det gjør jeg, markedet ikke). Da kan man velge om man vil sitte med aksjer den dagen meldingen kommer.
Takk for oppklaringen
OM Holding , we love you very very much. Takk for at du gav beskjed, makan til frekkhet skal en lete lenge etter. Nå får de jaggu levere varene før griskheten (ledelsen) skal ha enda mer gratis på bekostning av oss andre.
2 Likes
Hva tenker du da i forhold til det styreleder Ludvik sa nå at lønnsnivået i Norge er veldig lavt i forhold til utlandet mtp å tiltrekke seg en ny styreleder med relevant internasjonal erfaring? Jeg ser heller at de betaler premium lønn for å tiltrekkes de beste i markedet internasjonalt, både styreleder, ny CEO og evt andre.
Norge er et bakvendt molboland på det området, det tror jeg de fleste er enige om.
2 Likes